Sector News

Stryker acquires intensive-care product maker for $2.76 billion

February 3, 2016
Life sciences

Medical-device maker Stryker reached a deal to buy a 45-year-old manufacturer of health-care treatment products for hospitals for $2.76 billion.

Stryker is acquiring Sage Products from private equity firm Madison Dearborn Partners, the companies said in a statement Monday.

Cary, Ill.-based Sage, which had $430 million in revenue in its 2015 fiscal year, makes disposal products aimed primarily at intensive-care units and other hospital settings. Its products include solutions for patient cleaning, turning and positioning, oral care and skin preparation. Stryker sells products that are complementary to those produced by Sage, the companies said.

Stryker, based in Kalamazoo, Mich., said it would glean a $500 million tax benefit from the deal, which is expected to close in the second quarter.

“This acquisition aligns with Stryker’s focus on offering products and services that support a mindset of prevention, specifically in the area of ‘never events’ such as hospital-acquired infections,” Stryker CEO Kevin Lobo said in a statement.

Stryker raised its full-year 2016 earnings projection by 5 cents per share to a range of $5.55 to $5.75.

By Nathan Bomey

Source: USA Today

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.